NEJM CBD Effective Medicine v2

Breaking News: New Study Confirms CBD is Effective Medicine

Help Us Spread the Word
  •  
  •  
  •  
  •  
  •  
  •  

Please Share CBD Medical JournalNEJM Medical Study: CBD has been found effective in reducing seizures in young children with severe, drug-resistant forms of epilepsy. Over a 14 week trial, 120 patients where given either a placebo or a 20 mg does of cannabidiol (CBD). Those that received CBD during the trial, reported a 50% drop in the number of weekly seizures. The median average number of seizures dropped from 12.4 to 5.9 per week.

 

Moreover, 5% of patients saw total remission – 0 seizures!

Among those that received CBD, 5% stopped having seizures altogether. Consider this: there is currently no FDA-approved treatment for Dravet syndrome. None. And now CBD has the potential to become the first and only medicine found effective to treat a form of epilepsy so severe that it kills 1 in 5 by age 20.

epidiolex-cannabidiol-or-cbd-bottle-and-packaging
Epidiolex

The findings of this double-blind study were published this week in the New England Journal of Medicine (NEJM), and demonstrate the effectiveness of cannabidiol (CBD) | Epidiolex in treating severe drug-resistant forms of epilepsy such as Dravet syndrome. CBD is the principle non-psychoactive compound found in marijuana and hemp. For this study, CBD was provided in the form of Epidiolex – a marijuana based formulation of CBD manufactured by GW Pharmaceuticals. More on GW Pharma in a bit.

 

And yet just this week, ‘acting’ DEA Chief Chuck Rosenberg reiterated that in his view – ‘marijuana is not medicine.’ It would seem Chuck, that the New England Journal of Medicine may just disagree with you on that point. Maybe it’s a good thing your just ‘acting’ DEA Chief.

 

The fact that this trial’s findings were published in the NEJM – one of the most respected peer-reviewed medical journals published, is a very big deal and a huge endorsement as to the study’s authenticity, veracity and medical significance. It’s also a big thumbs up for Epidiolex, the CBD formulation used in the study.

 

There were some drawbacks found during the study. Of the 120 patients in the trial, 8 withdrew due to perceived side-effects which included fatigue, fever and severe diarrhea.

 

Dravet-syndrome-Epidiolex-poster
Dravet Syndrome Epidiolex Info Poster

The study was funded by GW Pharmaceuticals, a UK based pharmaceutical company that specializes in the development of plant-derived cannabinoid therapeutics. GW Pharmaceuticals manufactures Epidiolex, the marijuana based CBD medicine that was used in this study. Epidiolex is currently finishing Phase 3 clinical trials as a treatment for two severe forms of epilepsy: Dravet syndrome, and Lennox-Gastaut syndrome. Epidiolex is also being studied as a possible treatment for Tuberous Sclerosis and Infantile Spasms.

Epidiolex LGS CBD Info Poster
Epidiolex LGS CBD Info Poster

 

If you, or someone you know, is suffering from these severe forms of epilepsy – let them know that there may be help on the horizon. In addition, the patient’s physician can contact GW Pharma for more information on GW-sponsored clinical trails by emailing here: medicalinformation@gwpharm.com.

 

On NASDAQ: GWPH | For investor relations click here

Follow Me

Muenker D.C.

Publisher and Editor at CBD Medical Journal
Publisher and Editor of the CBD Medical Journal, I am looking to Engage, Educate and Connect with medical marijuana entrepreneurs and cannabis enthusiasts from around the world.
Follow Me

Help Us Spread the Word
  •  
  •  
  •  
  •  
  •  
  •  

Leave a Reply